A three-dimensional viscoelastic model for cell deformation with experimental verification H Karcher, J Lammerding, H Huang, RT Lee, RD Kamm, ... Biophysical journal 85 (5), 3336-3349, 2003 | 280 | 2003 |
The “efficacy-effectiveness gap”: historical background and current conceptualization C Nordon, H Karcher, RHH Groenwold, MZ Ankarfeldt, F Pichler, ... Value in Health 19 (1), 75-81, 2016 | 154 | 2016 |
Force-induced focal adhesion translocation: effects of force amplitude and frequency PJ Mack, MR Kaazempur-Mofrad, H Karcher, RT Lee, RD Kamm American journal of physiology-Cell Physiology 287 (4), C954-C962, 2004 | 99 | 2004 |
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second … B Amzal, S Fu, J Meng, J Lister, H Karcher PloS one 12 (9), e0184423, 2017 | 60 | 2017 |
Role of simulation in understanding biological systems MR Kaazempur-Mofrad, M Bathe, H Karcher, HF Younis, HC Seong, ... Computers & structures 81 (8-11), 715-726, 2003 | 50 | 2003 |
Exploring the molecular basis for mechanosensation, signal transduction, and cytoskeletal remodeling MRK Mofrad, NA Abdul-Rahim, H Karcher, PJ Mack, B Yap, RD Kamm Acta biomaterialia 1 (3), 281-293, 2005 | 44 | 2005 |
Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer disease: a systematic review and meta-analysis J Martinkova, FC Quevenco, H Karcher, A Ferrari, EC Sandset, C Szoeke, ... JAMA Network Open 4 (9), e2124124-e2124124, 2021 | 39 | 2021 |
Nivolumab versus cabozantinib: comparing overall survival in metastatic renal cell carcinoma W Wiecek, H Karcher PLoS One 11 (6), e0155389, 2016 | 37 | 2016 |
From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics J Yu, H Karcher, AL Feire, PJ Lowe The AAPS journal 13, 169-178, 2011 | 23 | 2011 |
Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies CR Baumal, TL Sørensen, H Karcher, RL Freitas, A Becher, S Balez, ... Acta Ophthalmologica 101 (2), 123-139, 2023 | 22 | 2023 |
A coarse-grained model for force-induced protein deformation and kinetics H Karcher, SE Lee, MR Kaazempur-Mofrad, RD Kamm Biophysical journal 90 (8), 2686-2697, 2006 | 19 | 2006 |
Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis RP Finger, N Dennis, R Freitas, A Quenechdu, A Clemens, H Karcher, ... Advances in Therapy 39 (8), 3425-3448, 2022 | 15 | 2022 |
Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration : a systematic review of real-world evidence CC Wykoff, H Matsumoto, MR Barakat, H Karcher, A Lozama, A Mayhook, ... Retina (Philadelphia, Pa.), 2023 | 13 | 2023 |
Anti–vascular endothelial growth factor treatment discontinuation and interval in neovascular age-related macular degeneration in the United States SJ Bakri, H Karcher, S Andersen, EH Souied American Journal of Ophthalmology 242, 189-196, 2022 | 12 | 2022 |
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison C Porta, C Szczylik, R Casciano, S Fu, B Amzal, J Lister, H Karcher, ... Critical Reviews in Oncology/Hematology 139, 143-148, 2019 | 11 | 2019 |
4 Continuum elastic or viscoelastic models for the cell MRK Mofrad, H Karcher, RD Kamm This page intentionally left blank, 71, 2006 | 10 | 2006 |
Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: a case study using the SOHO database C Nordon, T Bovagnet, M Belger, J Jimenez, R Olivares, ... Schizophrenia Research 193, 146-153, 2018 | 9 | 2018 |
Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration JM Coney, R Zubricky, SB Sinha, N Sonbolian, L Zhou, TP Hull, SA Lewis, ... International Journal of Retina and Vitreous 9 (1), 8, 2023 | 7 | 2023 |
The treatment patterns with brolucizumab in Germany (realize) study: a retrospective cohort study based on longitudinal prescription data RG Liegl, H Karcher, S Chetty-Mhlanga, F Igwe, R Freitas Ophthalmology and Therapy 12 (1), 195-208, 2023 | 6 | 2023 |
One-year brolucizumab outcomes in neovascular age-related macular degeneration from a large united states cohort in the iris® registry MW MacCumber, CC Wykoff, H Karcher, E Adiguzel, SB Sinha, ... Ophthalmology 130 (9), 937-946, 2023 | 5 | 2023 |